======= TUT1 =======
== Gene Information ==
* **Official Symbol**: TUT1
* **Official Name**: terminal uridylyl transferase 1, U6 snRNA-specific
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=64852|64852]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q9H6E5|Q9H6E5]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=TUT1&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20TUT1|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/610641|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Poly(A) polymerase that creates the 3'-poly(A) tail of specific pre-mRNAs. Localizes to nuclear speckles together with PIP5K1A and mediates polyadenylation of a select set of mRNAs, such as HMOX1. In addition to polyadenylation, it is also required for the 3'-end cleavage of pre-mRNAs: binds to the 3'UTR of targeted pre-mRNAs and promotes the recruitment and assembly of the CPSF complex on the 3'UTR of pre-mRNAs. In addition to adenylyltransferase activity, also has uridylyltransferase activity. However, the ATP ratio is higher than UTP in cells, suggesting that it functions primarily as a poly(A) polymerase. Acts as a specific terminal uridylyltransferase for U6 snRNA in vitro: responsible for a controlled elongation reaction that results in the restoration of the four 3'-terminal UMP-residues found in newly transcribed U6 snRNA. Not involved in replication- dependent histone mRNA degradation. {ECO:0000269|PubMed:16790842, ECO:0000269|PubMed:18288197, ECO:0000269|PubMed:21102410}.
|PAP assoc|
|RRM 1|
|RNA uridylyltransferase activity|
|polynucleotide adenylyltransferase activity|
|pre-mRNA cleavage required for polyadenylation|
|mRNA cleavage involved in mRNA processing|
|histone mRNA catabolic process|
|mRNA cleavage and polyadenylation specificity factor complex|
|mRNA cleavage|
|mRNA polyadenylation|
|histone mRNA metabolic process|
|RNA polyadenylation|
|snRNA processing|
|snRNA metabolic process|
|mRNA 3-UTR binding|
|mRNA 3-end processing|
|RNA 3-end processing|
|RNA phosphodiester bond hydrolysis|
|nuclear-transcribed mRNA catabolic process|
|mRNA catabolic process|
|RNA catabolic process|
|nucleic acid phosphodiester bond hydrolysis|
|enzyme binding|
|nucleobase-containing compound catabolic process|
|ncRNA processing|
|nuclear speck|
|heterocycle catabolic process|
|cellular nitrogen compound catabolic process|
|aromatic compound catabolic process|
|ncRNA metabolic process|
|mRNA processing|
|organic cyclic compound catabolic process|
|mRNA metabolic process|
|nucleolus|
|RNA processing|
|cellular macromolecule catabolic process|
|macromolecule catabolic process|
|RNA binding|
|ATP binding|
|RNA metabolic process|
|negative regulation of gene expression|
|organic substance catabolic process|
|cellular catabolic process|
|gene expression|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp453|B02 10μM R08 exp453]]|-2.2|
|[[:results:exp75|MK-1775 0.32μM R02 exp75]]|-2.08|
|[[:results:exp351|Dexamethasone 0.006μM R07 exp351]]|-2.03|
|[[:results:exp287|HMS-I2 5μM R06 exp287]]|-1.89|
|[[:results:exp97|BI-6727 0.0125μM R03 exp97]]|-1.86|
|[[:results:exp318|ABT-702 5μM R07 exp318]]|-1.82|
|[[:results:exp60|Vinblastine 0.002μM R01 exp60]]|-1.75|
|[[:results:exp229|Dimethyloxaloylglycine 100μM R05 exp229]]|-1.73|
|[[:results:exp475|CyclicAMP 200μM R08 exp475]]|-1.71|
|[[:results:exp335|Aminopterin 0.005μM R07 exp335]]|1.76|
|[[:results:exp240|Pyridostatin 4μM R05 exp240]]|1.79|
|[[:results:exp259|6-Thio-2-deoxyguanosine 2μM R06 exp259]]|2.4|
^Gene^Correlation^
|[[:human genes:c:cd2bp2|CD2BP2]]|0.598|
|[[:human genes:h:hars|HARS]]|0.5|
|[[:human genes:n:n6amt1|N6AMT1]]|0.439|
|[[:human genes:s:snapc5|SNAPC5]]|0.437|
|[[:human genes:n:ncdn|NCDN]]|0.423|
|[[:human genes:a:aar2|AAR2]]|0.412|
|[[:human genes:p:ppp6c|PPP6C]]|0.402|
Global Fraction of Cell Lines Where Essential: 699/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|1/1|
|909776.0|1/1|
|bile duct|27/28|
|blood|24/28|
|bone|25/26|
|breast|32/33|
|central nervous system|51/56|
|cervix|4/4|
|colorectal|16/17|
|esophagus|13/13|
|fibroblast|1/1|
|gastric|16/16|
|kidney|21/21|
|liver|19/20|
|lung|73/75|
|lymphocyte|16/16|
|ovary|22/26|
|pancreas|22/24|
|peripheral nervous system|15/16|
|plasma cell|15/15|
|prostate|1/1|
|skin|23/24|
|soft tissue|9/9|
|thyroid|2/2|
|upper aerodigestive|20/22|
|urinary tract|27/29|
|uterus|5/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 862
* **Expression level (log2 read counts)**: 4.84
{{:chemogenomics:nalm6 dist.png?nolink |}}